SavedAdd your journal

Journals / Maltepe Tıp Dergisi / 2020 / Cilt: 12 - Sayı: 2

Propylthiouracil induced p-ANCA+ pyoderma gangrenosum: Case report and review of literature

Sadettin USLU
Aydan KÖKEN AVŞAR
Ali KARAKAS
Pages
59–62
Publication Date
2020-08-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to present development of PG with p-ANCA positivity in a patient who had been using PTU for a long time and to discuss the current literature with this case-based review.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Öz Propylthiouracil (PTU) is a medication commonly used in the treatment of hyperthyroidism and is associated with the development of antineutrophil cytoplasmic antibodies (ANCA) in 20% of patients treated for Graves’ disease [1], [2].
📊
Key Findings & Data:ANCA-positive PTU-induced pyoderma gangrenosum (PG) was first identified in 1999 by Darben et al. [1].
💡
Conclusion & Impact:We aimed to present development of PG with p-ANCA positivity in a patient who had been using PTU for a long time and to discuss the current literature with this case-based review.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Anahtar Kelimeler ANCA · PTU · Pyoderma Gangrenosum

Özet

Öz Propylthiouracil (PTU) is a medication commonly used in the treatment of hyperthyroidism and is associated with the development of antineutrophil cytoplasmic antibodies (ANCA) in 20% of patients treated for Graves’ disease [1], [2]. ANCA-positive PTU-induced pyoderma gangrenosum (PG) was first identified in 1999 by Darben et al. [1]. ANCAs are found in the blood of many patients with necrotizing systemic vasculitis and in some patients with neutrophilic dermatoses such as drug-induced vasculitis, Sweet’s syndrome, Behçet's disease and PG. Some reports have described the ANCA phenomenon in patients with PG or in neutrophilic dermatosis with the characteristics of PG [3]. . We aimed to present development of PG with p-ANCA positivity in a patient who had been using PTU for a long time and to discuss the current literature with this case-based review.

🔖

Cite This Article

USLU, S., AVŞAR, A. K., KARAKAS, A. (2020). Propylthiouracil induced p-ANCA+ pyoderma gangrenosum: Case report and review of literature. Maltepe Tıp Dergisi, Cilt: 12 - Sayı: 2, 59–62. https://ajindex.com/articles/230958

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. T. Darben, J. Savige, R. Prentice, B. Paspaliaris, and J. Chick, “Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil,” Australas. J. Dermatol., 1999.
  2. R. M. Miller, T. A. Darben, J. Nedwich, and J. Savige, “Propylthiouracil-induced antineutrophil cytoplasmic antibodies in a patient with Graves’ disease and a neutrophilic dermatosis [13],” British Journal of Dermatology. 1999.
  3. K. Gungor, S. Gonen, G. Kisakol, O. Dikbas, and A. Kaya, “ANCA positive propylthiouracil induced pyoderma gangrenosum [2],” Journal of Endocrinological Investigation. 2006. B. R., “Management of pyoderma gangrenosum - An update,” Indian J. Dermatol. Venereol. Leprol., 2004.
  4. J. Reichrath, G. Bens, A. Bonowitz, and W. Tilgen, “Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients,” Journal of the American Academy of Dermatology. 2005.
  5. P. Al Ghazal, A. Körber, J. Klode, and J. Dissemond, “Investigation of new co-factors in 49 patients with pyoderma gangrenosum,” JDDG J. der Dtsch. Dermatologischen Gesellschaft, 2012. S. B. Hong and M. H. Lee, “A Case of Propylthiouracil-Induced Pyoderma gangrenosum Associated with Antineutrophil Cytoplasmic Antibody,” Dermatology, 2004. B.-V. A. et al., “Neutrophilic dermatosis associated with propylthiouracil-induced p-ANCA (p-antineutrophil cytoplasmic antibodies),” Ann. Dermatol. Venereol., 2005.
  6. J. W. Seo, H. H. Son, J. H. Choi, and S. K. Lee, “A case of p-ANCA-positive propylthiouracil-induced pyoderma gangrenosum,” Ann. Dermatol., 2010. J. Y. Noh et al., “Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves’ disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations,” Clin. Endocrinol. (Oxf)., 2001. N. Sera et al., “Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves’ disease,” Thyroid, 2000.
  7. J. E. Gunton, J. Stiel, P. Clifton-Bligh, E. Wilmshurst, and A. McElduff, “Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication,” Eur. J. Endocrinol., 2000.
  8. M. C. Slot, T. P. Links, C. A. Stegeman, and J. W. C. Tervaert, “Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study,” Arthritis Care Res., 2005. S. S. Dhillo